Albert Bourla, Pfizer CEO (Matthew Busch/Bloomberg via Getty Images)
September 15, 2022 10:06 AM EDTUpdated September 19, 04:02 AM
R&D

Up­dat­ed: Striv­ing for 2023 launch, Pfiz­er touts topline PhI­II win for an­oth­er mass mar­ket vac­cine

Amber Tong

One of the vac­cines that Pfiz­er has pegged for a 2023 launch has hit the mark in Phase III, set­ting up a fil­ing by the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times